Company intelligence / Profile preview

Circle Biopharma

South San Francisco, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Circle Pharma is a clinical-stage biopharmaceutical company developing cell-permeable macrocycle drugs targeting cyclins, key regulators in cancer. Its lead candidate, CID-078, is a first-in-class oral cyclin A/B RxL inhibitor currently advancing through clinical trials. The company has presented promising preclinical and early clinical data at major conferences such as AACR and SABCS[3].

Therapeutic areas: Oncology
Modalities: Macrocycles (cell-permeable macrocycles)Oral therapeutics
Industry: Biotech

Drug pipeline

1 asset

CT1812

Phase 2

Indications: Alzheimer's disease

Partnerships

Boehringer Ingelheim collaboration for advancing macrocycle therapeutics[5]

Beyond the preview

Go deeper on Circle Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Circle Biopharma.

Explore the full profile